You’ve probably given little thought to the slip of paper your GP hands you when she sends you off for a blood test. After all, you’re likely to have more important things to worry about. But the next…
Articles on Big Pharma
Displaying 101 - 119 of 119 articles
The earthquake in the Northern Italian town of Medolla this May devastated the local community, killing 17 people and leaving 14,000 homeless. Because Medolla is the manufacturing epicentre of the Italian…
New medicines must be approved as safe, efficacious and of good quality before they can be prescribed. But authors of two recent articles in the British Medical Journal argue that governments should introduce…
If it involved the record industry we’d call it payola: undisclosed kickbacks to radio station executives, owners and disk jockeys to boost broadcasts and thus record sales. In the pharmaceutical industry…
Pharmaceutical companies will be required to disclose more details about their financial ties to doctors under a revised self-regulatory code, but they have resisted calls to name doctors individually…
Two large multinational pharmaceutical companies are fighting for patents and monopoly pricing in Indian courts. The outcomes of the cases – involving Novartis and Bayer – are likely to determine the country’s…
Anti-cholesterol drug Lipitor® (atorvastatin) has been estimated to generate Pfizer revenues of more than $130bn worldwide. Australian taxpayers’ share of this is about $7bn, through subsidies from the…
TRANSPARENCY AND MEDICINE – A series examining issues from ethics to the evidence in evidence-based medicine, the influence of medical journals to the role of Big Pharma in our present and future health…
How would you feel if your local GP or specialist was pocketing money from a drug company to promote its products? If your gut tells you that this falls squarely into the category of Very Bad Ideas then…
The 2008 global financial crisis and an impending “patent cliff” have had a profound impact on the profitability of the pharmaceutical industry – they have made it change how it works. So, to maintain…
Many pharmaceutical companies are having to re-examine their product portfolio because of the difficult economic climate. New uses for established drugs affords a way for these companies to maximise financial…
It’s the pharmaceutical industry equivalent of the butterfly effect: a drug manufacturing plant in Ohio shuts down production after regulators on two continents uncover contamination problems. Suddenly…
The enormous medical impact of modern pharmaceuticals has on occasion been matched by some large-scale litigation regarding adverse events. The Vioxx litigation in Australia and elsewhere is one such recent…
First it was the Pharmacy Guild’s deal with Blackmores that raised ethical concerns. Now it’s the Guild and Pfizer. Both deals involve undisclosed payments from drug companies to Guild subsidiaries to…
Welcome to “The most powerful companies you’ve never heard of” – an ongoing series from The Conversation that sheds light on big companies with low profiles. Today, Deakin University’s Philip Soos examines…
This week Radio National’s Background Briefing looks at how pharmaceutical companies market their products to doctors. The program is presented by Ray Moynihan, an award-winning journalist, columnist at…
“Would you like the generic brand of that medicine?” It’s a question you’ve probably been asked, or at least heard, when picking up a prescription at your local pharmacy. It’s likely you were told the…
Any parent who watches kids’ weekend footy knows that if the ref misses a breach of the rules, merry hell breaks loose. But referees are human and sometimes make errors. We forgive the odd one pretty quickly…
The US Court of Appeals for the Federal Circuit has found Myriad Genetics is entitled to patents on two sets human genetic mutations used to predict if women have an increased risk of breast and ovarian…
Top contributors
-
Associate professor, Department of Family and Community Medicine, University of Toronto; York University, Canada; University of Sydney
-
Senior Research Manager, University of Sydney and Honorary Assistant Professor, Bond University
-
Professor of Bioethics, Macquarie University
-
Associate Professor, School of Law, University of Canberra
-
Professor of Bioethics & Medicine, Sydney Health Ethics, Haematologist/BMT Physician, Royal North Shore Hospital and Director, Praxis Australia, University of Sydney
-
Assistant Professor of Resource Economics, UMass Amherst
-
Professor in Pharmaceutical Policy, School of Pharmacy and Charles Perkins Centre, University of Sydney
-
Macquarie University Research Fellow, Macquarie University
-
Professor of Medicine and Public Health, University of Colorado Anschutz
-
Adjunct associate, Lancaster University
-
Associate Professor Politics and Policy Studies, Deakin University
-
Health activist, Medreach Pty Ltd., Bond University
-
Research Fellow, Asia Pacific Social Impact Centre, The University of Melbourne
-
Professor of Accounting, Durham University
-
Associate professor, School of Biomedical Sciences, University of Leeds